BACKGROUND AND PURPOSE: The high predisposition to Torsade de Pointes (TdP) in dogs with chronic AV-block (CAVB) is well documented. The anti-arrhythmic efficacy and mode of action of Ca(2+) channel antagonists, flunarizine and verapamil against TdP were investigated. EXPERIMENTAL APPROACH: Mongrel dogs with CAVB were selected based on the inducibility of TdP with dofetilide. The effects of flunarizine and verapamil were assessed after TdP and in different experiments to prevent dofetilide-induced TdP. Electrocardiogram and ventricular monophasic action potentials were recorded. Electrophysiological parameters and short-term variability of repolarization (STV) were determined. In vitro, flunarizine and verapamil were added to determine their effect on (i) dofetilide-induced early after depolarizations (EADs) in canine ventricular myocytes (VM); (ii) diastolic Ca(2+) sparks in RyR2(R4496+/+) mouse myocytes; and (iii) peak and late I(Na) in SCN5A-HEK 293 cells. KEY RESULTS: Dofetilide increased STV prior to TdP and in VM prior to EADs. Both flunarizine and verapamil completely suppressed TdP and reversed STV to baseline values. Complete prevention of TdP was achieved with both drugs, accompanied by the prevention of an increase in STV. Suppression of EADs was confirmed after flunarizine. Only flunarizine blocked late I(Na). Ca(2+) sparks were reduced with verapamil. CONCLUSIONS AND IMPLICATIONS: Robust anti-arrhythmic efficacy was seen with both Ca(2+) channel antagonists. Their divergent electrophysiological actions may be related to different additional effects of the two drugs.
BACKGROUND AND PURPOSE: The high predisposition to Torsade de Pointes (TdP) in dogs with chronic AV-block (CAVB) is well documented. The anti-arrhythmic efficacy and mode of action of Ca(2+) channel antagonists, flunarizine and verapamil against TdP were investigated. EXPERIMENTAL APPROACH: Mongrel dogs with CAVB were selected based on the inducibility of TdP with dofetilide. The effects of flunarizine and verapamil were assessed after TdP and in different experiments to prevent dofetilide-induced TdP. Electrocardiogram and ventricular monophasic action potentials were recorded. Electrophysiological parameters and short-term variability of repolarization (STV) were determined. In vitro, flunarizine and verapamil were added to determine their effect on (i) dofetilide-induced early after depolarizations (EADs) in canine ventricular myocytes (VM); (ii) diastolic Ca(2+) sparks in RyR2(R4496+/+) mouse myocytes; and (iii) peak and late I(Na) in SCN5A-HEK 293 cells. KEY RESULTS:Dofetilide increased STV prior to TdP and in VM prior to EADs. Both flunarizine and verapamil completely suppressed TdP and reversed STV to baseline values. Complete prevention of TdP was achieved with both drugs, accompanied by the prevention of an increase in STV. Suppression of EADs was confirmed after flunarizine. Only flunarizine blocked late I(Na). Ca(2+) sparks were reduced with verapamil. CONCLUSIONS AND IMPLICATIONS: Robust anti-arrhythmic efficacy was seen with both Ca(2+) channel antagonists. Their divergent electrophysiological actions may be related to different additional effects of the two drugs.
Authors: Gudrun Antoons; Avram Oros; Jet D M Beekman; Markus A Engelen; Marien J C Houtman; Luiz Belardinelli; Milan Stengl; Marc A Vos Journal: J Am Coll Cardiol Date: 2010-02-23 Impact factor: 24.094
Authors: S G Priori; C Napolitano; N Tiso; M Memmi; G Vignati; R Bloise; V Sorrentino; G A Danieli Journal: Circulation Date: 2001-01-16 Impact factor: 29.690
Authors: Morten B Thomsen; S Cora Verduyn; Milan Stengl; Jet D M Beekman; Geert de Pater; Jurren van Opstal; Paul G A Volders; Marc A Vos Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos Journal: Br J Pharmacol Date: 2014-02 Impact factor: 8.739
Authors: P Champeroux; J Y Le Guennec; S Jude; C Laigot; A Maurin; M L Sola; J S L Fowler; S Richard; J Thireau Journal: Br J Pharmacol Date: 2016-01-14 Impact factor: 8.739
Authors: P Champeroux; J Thireau; S Judé; C Laigot-Barbé; A Maurin; M L Sola; J S L Fowler; S Richard; J Y Le Guennec Journal: Br J Pharmacol Date: 2015-03-26 Impact factor: 8.739
Authors: Alexandre Bossu; Rosanne Varkevisser; Henriette D M Beekman; Marien J C Houtman; Marcel A G van der Heyden; Marc A Vos Journal: J Cardiovasc Pharmacol Date: 2017-06 Impact factor: 3.105
Authors: Anne-Françoise Schlit; Annie Delaunois; Aurore Colomar; Branderley Claudio; Luca Cariolato; Rossen Boev; Jean-Pierre Valentin; Christopher Peters; Victor S Sloan; Jürgen W G Bentz Journal: Pharmacol Res Perspect Date: 2017-04-21
Authors: Alexandre Bossu; Marien J C Houtman; Veronique M F Meijborg; Rosanne Varkevisser; Henriette D M Beekman; Albert Dunnink; Jacques M T de Bakker; Nevena Mollova; Sridharan Rajamani; Luiz Belardinelli; Marcel A G van der Heyden; Marc A Vos Journal: Br J Pharmacol Date: 2018-05-06 Impact factor: 8.739